Skip to main content

Table 5 Comparison between the patients with HCC and those without HCC in all the 231 patients

From: PNPLA3 I148M associations with liver carcinogenesis in Japanese chronic hepatitis C patients

 

Patients with HCC

Patients without HCC

Comparison between patients with HCC and those without HCC

Multiple regression analysis for factors associated with HCC development

(n = 48)

(n = 183)

Odds ratio (95% confidence interval)

p

Age (yrs)

70.5 ± 7.8

60.9 ± 11.2

p < 0.0001

1.12 (1.07 - 1.17)

p < 0.0001

Gender (male/female)

25/23

78/105

NS

1.83 (0.90 - 3.71)

p = 0.0936

BMI (kg/m2)

23.1 ± 3.9

22.3 ± 3.4

NS

  

Response to IFN treatment (NVR/no past IFN therapy)

17/31

77/106

NS

  

PNPLA3 (GG/CC・CG)

34/14

156/27

p = 0.0200

2.62 (1.15 - 5.96)

p = 0.0218

AST (IU/L)

72.1 ± 54.8

53.0 ± 46.4

p = 0.0158

  

ALT (IU/L)

60.4 ± 46.4

63.5 ± 82.1

NS

  

γ-GTP (IU/L)

50.4 ± 34.9

61.1 ± 85.8

NS

  

Albumin (g/dL)

3.5 ± 0.7

4.2 ± 0.5

p < 0.0001

  

Total bilirubin (mg/dL)

1.3 ± 0.97

0.9 ± 0.76

p = 0.0010

  

Platelet count (x104/μL)

9.5 ± 4.2

14.4 ± 5.4

p < 0.0001

  

Prothrombin time (%)

83.7 ± 13.90

97.1 ± 18.8

p < 0.0001

  

Hyaluronic acid (ng/mL)

473.8 ± 480.9

181.1 ± 267.2

p < 0.0001

  

α-fetoprotein (ng/mL)

308.6 ± 1134.9

20.8 ± 113.2

p = 0.0009

  

PIVKA-II(mAU/mL)

40.25 ± 43.22

20.56 ± 9.93

p = 0.0030

  

HCV genotype (1/2/3)

42/6/0

169/35/2

NS

  

HCV RNA (log IU/mL)

6.0 ± 1.1

6.2 ± 1.0

NS

  

Velocity of shear wave (m/s)

2.19 ± 0.64

1.57 ± 0.52

p < 0.0001

  
  1. HCC, hepatocellular carcinoma; BMI, body mass index; IFN, interferon; NVR, non-virological response; PNPLA3, patatin-like phospholipase domain-containing 3; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyltranspeptidase; PIVKA-II, protein induced by Vitamin K absence or antagonist-II; NS, not significant.